Tag: Cellestial
-
Best Industry and Not for Profit Collaboration: Finalists
The annual One Nucleus Awards dinner celebrates the excellence of the diverse Life Sciences sector, recognising all parts of the community. One Nucleus believe that it is the interactions and dynamics of the entire ecosystem that lead to successful value and impact creation, the vision that resonates with our team’s. This year, the collaboration between…
-
Back at it again in Boston
This week, Dr Nat Hastings represented innovative research into astrocyte pathology in Parkinson’s at the 14th Alzheimer’s & Parkinson’s Drug Development Summit on behalf of Cellestial Health at Hyatt Regency Boston Harbor. Astrocytic lineage is one of the most populous cell types in the brain, yet the damage Parkinson’s pathology does to it remains underappreciated.…
-
BioSeed 2026: What Matters
On Monday 19th of January, the Cellestial Team attended BioSeed by OBN to re-connect with the London life sciences community and share why our approach to astrocytic network restoration matters in Parkinson’s. ✦ For brain cells, we are looking to reduce the burden of abnormal protein aggregates and inflammation via a novel mechanism✦ For people…
-
Cellestial Health officially opens Seed funding round
On Monday 17th of November, at the LSX Investival 2025 and at the start of the Jeffries week in London, Dr Nat Hastings (CEO) and Dr Peter Bach (Head of Drug Development) of Cellestial Health have officially opened the Seed fundraise. This follows on from a strong year post-Pre-Seed funding, featuring:✦ Proof-of-concept studies in disease-relevant…
-
BMCS and Parkinson’s UK: New Approaches to the Treatment of Parkinson’s
Dr Nat Hastings represented Cellestial Health at the RSC BMCS and Parkinson’s UK “New Approaches to the Treatment of Parkinson’s” conference on Wednesday 12th, alternating between the corporate exhibitor stand, academic poster presenter, and an audience member of the many insightful talks at the majestic Royal Society of Chemistry halls. Here are the highlights of…
-
One Nucleus #BioWednesday: Ones to Watch in Neuroscience
On Wednesday 22nd of October, a number of select innovative companies presented 5-minute pitches at the One Nucleus BioWednesday evening dedicated to Neuroscience. The opening pitch was delivered by Dr Nat Hastings on behalf of Cellestial Health, discussing our pipeline of small molecule therapeutics designed to protect astrocytic networks and slow down Parkinson’s. A mix…
-
Dazzling Dinner with Cambridge Independent
On Thursday 25th of September Cambridge Independent hosted a Gala dinner to celebrate the 2025 edition of the #CIBusinessAwards at King’s College, Cambridge. The event celebrated a range of local businesses from all sectors, from property management to educational opportunities. It is not easy to stand out in such a diverse environment, and in a…
-
OBN #BioTuesday: Founders’ Journey
On Tuesday 23rd of September OBN welcomed an audience of life science experts to one of its regular #BioTuesday events, this time kindly hosted by ARC Advanced Research Clusters. The topic of the evening was the Founders’ Journey. The panel discussion chaired by Angela Hobbs invited questions around building a business, hiring, managing finances and…
-
Parkinson’s UK: Further Funding for Pioneering Approach
Parkinson’s UK awarded Cellestial Health £55,000 to continue exploring networks of brain cells that may hold answers for new treatments for Parkinson’s. There are many different types of cells in the brain. We know that in Parkinson’s, brain cells that produce dopamine become damaged and start to die over time. However, it’s possible that other…
-
Finalists: OBN Awards 2025
Cellestial Health has been honoured as one of the top four companies in the BioSeed “Ones to Watch” category: https://obn.glueup.com/event/obn-awards-2025-128684/2025-finalists-announced.html#2025-finalists-announced The Awards, now in the 17th year, celebrate innovation and outstanding achievement across the Life Sciences industry. Being the company “to watch” is thrilling and prestigious, but also comes with a weight of expectation and…